Core Insights - China's innovative drug sector continues to thrive, with significant business development (BD) transactions occurring in early 2026, indicating strong global recognition of Chinese innovation [1][2] - Morgan Stanley's report highlights the long-term potential of China's pharmaceutical industry, emphasizing the importance of globalization and industry differentiation [1][2] Group 1: Business Development Transactions - As of February 15, 2026, there have been 39 license-out transactions in China's innovative drug sector, with upfront payments totaling approximately $2.953 billion and total transaction values exceeding $49 billion [1] - In 2025, the total BD transaction amount for Chinese innovative drugs reached $135.7 billion, surpassing that of the United States for the first time [2] - The first 49 days of 2026 have already seen transaction volumes exceed any single quarter in 2025, reflecting a robust growth trend [2] Group 2: Key Companies and Developments - Morgan Stanley identifies Heng Rui Medicine as a top pick, expecting accelerated sales growth and positive momentum in new cooperative transactions for 2026 [2] - The approval of the innovative drug, phosphor-lucotidine cream, by Kangzhe Pharmaceutical marks a significant milestone, being the first targeted drug for vitiligo in China [2] - Kangzhe Pharmaceutical's planned spin-off of its subsidiary, Demai Pharmaceutical, for a Hong Kong listing is seen as a strategic move to focus on core therapeutic areas while potentially enhancing short-term profitability [3] Group 3: Market Trends and Future Outlook - The innovative drug sector is experiencing a clear division, with companies reliant on generic drugs facing performance pressures, while those with sustainable innovation capabilities are positioned for high-quality growth [3][4] - The current BD trend is shifting towards early-stage research projects, with over 50% of recent transactions involving preclinical projects [5] - Companies like Kangfang Biotech are committed to expanding their global footprint and enhancing the international visibility of Chinese innovations in drug development [5]